Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC -- Ignore unavailable to you. Want to Upgrade?

To: Pancho Villa who wrote (1031)	2/13/1998 12:50:00 PM
From: WeirdPro Randy	Read Replies (1) \| Respond to of 1359

<<To All: click on the message I am replying to so that you see what I had to say last December about earnings for the quarter just reported. Look at the cash going down like hell and current liabilities are still at 30 million.>> I did look at your message (#954) and this is what it said........... <<Look at the staggering 42 million in current liabilities.>>............. So we burnt $19 million this previous quarter, but by your posts, it makes it appear as if we have reduced liabilities by $12 million.....?

To: Pancho Villa who wrote (1031)	2/14/1998 7:26:00 PM
From: Scott Pratho	Read Replies (1) \| Respond to of 1359

What I see in the earnings report is that IPIC paid $10Mill to Astra Merck in December 1997 in conjunction with the development of BEXTRA. The other $16Mill in cash burn could be seen as going toward paying down the current liabilities which decreased by $12Mill. By way of anecdote, I made a call to our hospital's echocardiogram tech. She stated that almost all she's done in the past several months are echo's to rule out heart valve problems in patients who took diet pills. She has found "hardly anything". She is quite bored doing these studies and said they are finally tapering off since nothing is turning up. I know this is not scientific. My next step is to poll the cardiologists. Let's just assume that this is true, that there really is no liability regarding the heart valve/Redux issue. Let's also assume that citicoline is efficacious in the treatment of acute ischemic stroke, an ailment for which there simply is not much to offer (and, indeed, the literature looks much better than a 50/50 approval scenario). If/when approved, citicoline will instantly be the standard of care in the management of acute ischemic stroke since it has little in the way of side effects and possibly a lot to offer. Recent numbers put the incidence of stroke at 700,000 per year in the U.S. At a nominal price of $1000 per treatment, that makes $700Mill (rough numbers I know). What if Bextra came to market. I would like to see an update on Bextra myself, but there must be something there for IPIC to put up the $10Mill. And Pagoclone...And LidoexNS... I don't pretend to know what the stock's next move will be, but I think the outlook for the company is much better than what I've read on this thread lately.